With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.192130-34-0,tert-Butyl 4-(2-aminoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
Cat. TsOH monohydrate was added to a suspension of methyl 14′-cyclohexyl-2,2- dimethylspiro[l,3-dioxane-5,7′-indolo[l,2-e][l,5]benzoxazocine]-H’-carboxylate in MeOH/THF 1:2 (0.03 M), and the solution was stirred at RT for 3 h. Filtration on a pad of neutral alumina using EtOAc as eluent afforded after evaporation of the solvent in vacuo methyl 14-cyclohexyl- 7, 7-bis(hydroxymethyl)-7,8-dihydro-6H-indolo[l,2-e][l,5]benzoxazocine- 11 -carboxylate (quant). This material was dissolved in dry MeCN (0.2M) and DIPEA (4.0 eq) and trifluoromethane sulfonic anhydride (3.5 eq) was added at 0 0C. The mixture was stirred at 0 0C for 15 min, then more DIPEA (4 eq) was added at RT. 7ert-butyl 4-(2-aminoethyl)piperazine-l- carboxylate (2 eq) was added, and the mixture was stirred at 70 0C for 1 h. After removal of the solvent in vacuo EtOAc was added, the solution was washed with H2O and brine, dried over Na2SO4 and the solvent was removed in vacuo. The crude methyl \-{2-[4-(tert- butoxycarbonyl)piperazin- 1 -yljethyl} – 14′-cyclohexylspiro[azetidine-3 ,7′-indolo[ 1 ,2- e][l,5]benzoxazocine]-l l’-carboxylate was taken in DCM/TFA 3:1 (0.13M) and stirred at RT for 2 h. The mixture was evaporated to dryness and the residual material was dissolved in EtOAc. The solution was washed with sat. aq. NaHCO3 and brine. The organic phase was dried overNa2SO4 and the solvent evaporated in vacuo. The residue was dissolved in dry dioxane (0.06M) and sulfamide (5 eq) was added. The mixture was stirred at reflux for 3 h, then overnight at RT. The residue obtained after evaporation was purified by FC (EtOAc/MeOH, 9:1) to afford the title compound in 40percent yield. (ES+) m/z 622 (M+H)+., 192130-34-0
As the paragraph descriping shows that 192130-34-0 is playing an increasingly important role.
Reference£º
Patent; ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA; WO2009/10783; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics